Hemispherx Biopharma Earnings Yield: -18.92%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
None selected
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
HEB Earnings Yield Rankings
| Overall | 10th percentile | 3926 of 4402 |
| Sector | 23rd percentile | 390 of 511 in Healthcare |
| Industry | 32nd percentile | 108 of 161 in Biotechnology |
HEB Earnings Yield Range, Past 5 Years
| Minimum | -53.33% | Mar 2005 |
| Maximum | -2.82% | Mar 2000 |
| Average |
About Earnings Yield
Earnings yield is earnings per share from the previous four quarters divided by the share price. It is the reciprocal of the P/E ratio. The earnings yield is quoted as a percentage, which illustrates the percentage of each dollar invested that was earned by the company during the past twelve months.
The earnings yield can be used to compare the earnings of a stock, sector or the whole market against bond yields. Generally, the earnings yields of equities are higher than the yield of risk-free treasury bonds. Financial theorists argue that this difference exists because stock earnings are riskier than bond coupon payments.
If a company has an earnings yield of 64%, investors are purchasing $0.64 of earnings per dollar invested.
Learn More
You may also be interested in these HEB related companies
HEB News
$HEB , I am early but bot it this morning. loking for a nice pop
about 9 days ago by 3DTRADINGTRADER
about 9 days ago by 3DTRADINGTRADER
UPDATE: Novavax, Hemispherx BioPharma, Biocryst Spiking Higher on H1N1 Reports in Mexico
Jan 23, 11:00AM Benzinga
Jan 23, 11:00AM Benzinga
Hemispherx Biopharma Receives U.S. Patent Office Notification of Two New Patents Granted for Alferon(R) LDO
Jan 17, 8:30AM GlobeNewswire
Jan 17, 8:30AM GlobeNewswire
Hemispherx Biopharma (HEB) Recieves FDA Extension for NDA for Treatment of Chronic Fatigue Syndrome
Jan 11, 8:35AM Street Insider
Jan 11, 8:35AM Street Insider
$HEB shares up 14% following extension to modify NDA for treatment of CFS
about 32 days ago by Street_Insider
about 32 days ago by Street_Insider
Hemispherx Biopharma (HEB) Gets Extension from FDA for CFS NDA Modification
Jan 11, 8:31AM Street Insider
Jan 11, 8:31AM Street Insider
FDA Grants $HEB Extension in Its Pending New Drug Application for the Treatment of Chronic Fatigue
about 32 days ago by Benzinga
about 32 days ago by Benzinga
What's up with $HEB !?!? Up 20% on more than 4X average daily volume.
about 69 days ago by swingtrades99
about 69 days ago by swingtrades99
Hemispherx Biopharma Announces Further Adjournment on Proposal Number 4 From the 2011 Annual Meeting of Stockholders
Nov 09, 4:13PM GlobeNewswire
Nov 09, 4:13PM GlobeNewswire
Hemispherx Biopharma Announces Financial Results for the Three Months Ended September 30, 2011
Nov 09, 12:26PM GlobeNewswire
Nov 09, 12:26PM GlobeNewswire
Hemispherx Biopharma, Inc. to Host Conference Call on Chronic Fatigue Syndrome Progress Thursday, October 27, 2011
Oct 24, 10:22AM GlobeNewswire
Oct 24, 10:22AM GlobeNewswire
Hemispherx Biopharma to Present at the Rodman and Renshaw 13th Annual Global Investment Conference
Sep 08, 4:30PM GlobeNewswire
Sep 08, 4:30PM GlobeNewswire
Hemispherx (HEB) Enters New Alferon N Injection Agreement with Armada Health Care
Sep 06, 8:40AM Street Insider
Sep 06, 8:40AM Street Insider
Hemispherx Biopharma Enters Into a Strategic Alliance With Armada Health Care for Alferon N Injection(R)
Sep 06, 8:30AM GlobeNewswire
Sep 06, 8:30AM GlobeNewswire
RT @Street_Insider Bird flu stocks moving for 2nd day $NVAX, $SVA, $BCRX $HEB $AVII // $SVA & then $AVII have strongest fundamentals overall
about 166 days ago by divtastic
about 166 days ago by divtastic
FDA authorizes new Hemispherx $HEB clinical trial of intranasal Ampligen(R); stock moving in pre-market
about 207 days ago by Street_Insider
about 207 days ago by Street_Insider
Hemispherx Biopharma Says FDA Lifts Hold On phase 2 Alferon Trial $heb
about 404 days ago by goldenchris
about 404 days ago by goldenchris
El CEO de $MCP me hace acordar al CEO delincuente de $HEB asi terminara.
about 409 days ago by sebatrader
about 409 days ago by sebatrader
Manuel Asensio has numerous SEC violations & should've stuck to SS: & reporting on Small Cap shams like $HEB. His $NFLX remarks = no value.
about 436 days ago by Legacy_Trades
about 436 days ago by Legacy_Trades
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| HEB | 0.37 | 0.04 | 10.45% | 50.13M |
| CMLS | 3.79 | 0.00 | 0.00% | 199.01M |
| AZN | 47.16 | -0.33 | -0.69% | 63.44B |
| GSK | 44.75 | -0.31 | -0.69% | 114.07B |
| APD | 90.40 | -0.65 | -0.71% | 19.03B |
| CGR | 1.36 | -0.05 | -3.55% | 222.88M |
| FMCN | 23.47 | -0.76 | -3.14% | 3.40B |
| RKT | 68.04 | 0.53 | 0.79% | 4.80B |
| CTL | 38.02 | 0.02 | 0.05% | 23.44B |
| GEOY | 22.18 | -0.84 | -3.65% | 492.17M |
